98895-60-4

Usage

Uses

Used in Pharmaceutical Industry:
(E)-2-cyano-3-cyclopropylacrylic acid is used as a starting material for the development of new drugs, leveraging its chemical properties to create a diverse range of pharmaceutical compounds. Its role in drug synthesis is crucial for the creation of novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, (E)-2-cyano-3-cyclopropylacrylic acid serves as a key building block for the manufacturing of complex molecules. Its unique structure allows for the formation of intricate molecular architectures, contributing to the advancement of organic chemistry.
Used in Agricultural Chemical Production:
(E)-2-cyano-3-cyclopropylacrylic acid is also utilized as a component in the production of agricultural chemicals. Its integration into the manufacturing process aids in the development of effective and targeted agrochemicals, enhancing crop protection and yield.
Used in Industrial Product Manufacturing:
This versatile compound finds application in the production of various industrial products, where its chemical properties are harnessed to improve the performance and functionality of the final products. Its use in this sector highlights the broad applicability of (E)-2-cyano-3-cyclopropylacrylic acid in different areas of industry and technology.

Upstream product

• 372-09-8 cyanoacetic acid 
• 1489-69-6 Cyclopropanecarboxaldehyde 

Downstream Products

• 1414353-67-5 (S)-2-(2-((4-amino-5-(2-fluoro-4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl)pyrrolidine-1-carbonyl)-3-cyclopropylacrylonitrile 
• 1414358-05-6 2-{2-[4-amino-5-(2-fluoro-4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-ylmethyl]pyrrolidine-1-carbonyl}-3-cyclopropylacrylonitrile 
• 1414353-63-1 (S)-2-(2-((4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl)pyrrolidine-1-carbonyl)-3-cyclopropylacrylonitrile 
• 1414357-15-5 (R)-2-(3-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)piperidine-1-carbonyl)-3-cyclopropylacrylonitrile 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors

Fibroblast growth factor receptor 4 (FGFR4) together with co-receptors modulate the activation of downstream proteins that regulate fundamental processes, and elevated FGFR4 activity is associated with Hepatocellular Carcinoma (HCC). Hence, FGFR4 is a promising therapeutic target for HCC. Based on BLU9931, we designed and synthesized a series of phenylquinazoline derivatives as novel inhibitors of FGFR4 through the covalent reversible strategy. Among them, a novel compound (C3) showed FGFR4 and cell proliferation inhibitory activity. Cellular mechanism studies demonstrated that compound C3 induced apoptosis via the FGFR4 signaling pathway blockage. Further mechanism study showed that C3 has the reversible covalent binding capacity, could be used as a reference for the development of novel FGFR4 covalent reversible inhibitors.

Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC

KRAS is the most frequently mutated oncogene and plays a predominant role in driving initiation and progression of multiple cancers. Attempts to degrade the oncogene KRASG12C with PROTAC strategy have been considered as an alternative strategy to combate cancers. However, the irreversible PROTACs may compromise the substoichiometric activity to decrease the potency. Herein, we report the development of YF135, the first reversible-covalent PROTAC capable of recruiting VHL mediated proteasomal degradation of KRASG12C. YF135 induces the rapid and sustained degradation of endogenous KRASG12C and attenuates pERK signaling in H358 and H23 cells in a reversible manner.

Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR

The clinical success of covalent kinase inhibitors in the treatment of EGFR-dependent non-small cell lung cancer (NSCLC) has rejuvenated the appreciation of reactive small molecules. Acquired drug resistance against first-line EGFR inhibitors remains the